MarginsXMarginsX
Home › Markets › Health Care › AYTU

Aytu BioPharma Inc. (AYTU)

AYTU trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.82
+1.68% on the day
Market cap
$19.8M
Nano cap
Revenue · 2026
$57.6M
-13.3% on 2025
Net income · 2026
-$14.3M
-24.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/0001437749-26-030908-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.

Profile

FieldValue
TickerAYTU on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001385818
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2026

LineValue
Revenue$57.6M
Net income-$14.3M
Operating income-$8.3M
Net margin-24.8%
Operating margin-14.4%
Revenue growth-13.3%
Cash$26.3M
Total assets$105.0M
P/E (computed)Net income was not positive
P/S (computed)0.3×

Warning signs

Cash runway
Cash-flow positive
$26.3M cash at June 30, 2026
Share count, 1 year
+9.6%
2025-09-15 to 2026-09-15 · +96.5% over 3 years
Going-concern doubt
No
10-K filed September 22, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-K 2026-09-22
Cash and burn$26.3M cash; operating cash flow $820K a quarter.Report 2026-06-30
Shares outstanding10,866,708 (2026-09-15); 9,911,913 a year earlier; 5,530,027 three years earlier.Cover page 2026-09-15
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorGrant Thornton LLP, Denver, Colorado, United StatesPCAOB Form AP 2026-10-01
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q4 2026
2026-06-30
$16.1M-$15K$4.4M$26.3M$11.0M$57.6M10-K 2026-09-22
Q3 2026
2026-03-31
$12.4M-$5.6M-$4.2M$26.7M$11.4M$56.6M10-Q 2026-05-13
Q2 2026
2025-12-31
$15.2M-$10.6M$3.7M$30.0M$11.9M$62.6M10-Q 2026-02-03
Q1 2026
2025-09-30
$13.9M$2.0M-$618K$32.6M$12.3M$63.7M10-Q 2025-11-13
Q4 2025
2025-06-30
$15.1M-$19.8M$2.8M$31.0M$12.8M$66.4M10-K 2026-09-22
Q3 2025
2025-03-31
$18.5M$4.0M-$6.5M$18.2M$11.4M$65.8M10-Q 2026-05-13
Q2 2025
2024-12-31
$16.2M$788K$2.9M$20.4M$15.9M$61.4M10-Q 2026-02-03
Q1 2025
2024-09-30
$16.6M$1.5M-$1.2M$20.1M$16.6M$63.9M10-Q 2025-11-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM 424B4
424B42025-06-09
Latest annual report
FORM 10-K
10-K2026-09-22
Latest quarterly / interim
FORM 10-Q
10-Q2026-05-13
Latest current report
FORM 8-K
8-K2026-11-16
Latest proxy
FORM DEFA14A
DEFA14A2026-10-27

Source: SEC EDGAR submissions feed, 910 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.7%
1 month-10.6%
3 months-22.6%
Year to date-31.5%
1 year-13.6%
From 52-week high-38.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CELUCelularity Inc.$0.6191-1.75%$20.1M
SHPHShuttle Pharmaceuticals Holdings Inc.$4.24-6.40%$20.2M
ATOSAtossa Therapeutics Inc.$1.93-1.53%$19.3M
IGCIGC Pharma Inc.$0.1750-0.57%$20.4M
CPHIChina Pharma Holdings Inc.$0.4800-7.35%$20.7M
COCPCocrystal Pharma Inc.$0.9777-0.24%$18.8M
TXMDTherapeuticsMD Inc.$1.81-3.21%$20.9M
LPCNLipocine Inc.$1.66-2.92%$18.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier